GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

SYH2069 Injection

Company
CSPC Ouyi Pharmaceutical Co., Ltd.
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Active, not recruiting NCT NCT07736391

    A Study of SYH2069 Injection in Healthy Participants

    Not yet reported CSPC Ouyi Pharmaceutical Co., Ltd. 104 participants Est. completion 2026-11-30 1 site Stand-alone
    Other conditions: Overweight or Obesity, Diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07796477

    A Study of SYH2069 Injection in Participants With T2DM Not Controlled With Diet/Exercise Alone or Metformin

    Not yet reported CSPC Ouyi Pharmaceutical Co., Ltd. 240 participants Est. completion 2027-10-19 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Not yet recruiting NCT NCT07803991

    Efficacy and Safety of SYH2069 Injection in Obese Participants Without Diabetes.

    Not yet reported CSPC Ouyi Pharmaceutical Co., Ltd. 360 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Overweight or Obesity
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: SYH2069 Injection, SYH2069 Injection (group 1), SYH2069 Injection (group 2), SYH2069 Injection (group 3), SYH2069 Injection (group 4)

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.